Ipamorelin
Ipamorelin scored 4.8 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Peptide → Growth / Repair Peptide.
Ipamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial (postoperative ileus, n=114) failed, per Beck 2014.
What is Ipamorelin?
Ipamorelin is a lab-made peptide that nudges your own pituitary to release a short pulse of growth hormone, and its biggest selling point is what it does not do. It is a selective agonist at the ghrelin receptor (GHS-R1a), and unlike the older peptides it replaced, it raises growth hormone without meaningfully spiking cortisol or prolactin, per Raun 1998. That clean profile is real and well-documented. The catch sits one layer down: almost none of the reasons people actually buy ipamorelin (fat loss, recovery, better sleep, anti-aging) have been tested in humans.
Here's the thing. The only completed human efficacy trial gave ipamorelin to 114 patients recovering from bowel surgery, and it failed, per Beck 2014. Development stopped there. So a peptide with a genuinely elegant mechanism carries a near-empty human outcomes file, and the score reflects that gap honestly: a clean, well-tolerated tool whose benefits remain mostly unproven in people.
Terminology
A few terms decide how you read everything below, because the gap between "the mechanism works" and "the outcome is proven" is where ipamorelin lives.
- Growth-hormone secretagogue (GHS): A compound that prompts your body to release its own growth hormone, rather than injecting growth hormone directly.
- GHS-R1a: The ghrelin receptor on pituitary cells. Ipamorelin binds here to trigger a growth-hormone pulse.
- IGF-1: Insulin-like growth factor 1. The downstream signal growth hormone produces; the marker you track and the pathway behind the cancer concern.
- Selectivity: Hitting the intended target (growth hormone) without dragging along unwanted hormones (cortisol, prolactin). Ipamorelin's defining feature.
- GHRP-6 / GHRP-2: Older growth-hormone-releasing peptides that also raise hunger, cortisol, or prolactin. Ipamorelin was built to avoid those effects.
- Postoperative ileus (POI): The temporary gut shutdown after abdominal surgery. The one human condition ipamorelin was formally tested for, where it failed.
- PCAC: The FDA's Pharmacy Compounding Advisory Committee, which reviews whether peptides can be legally compounded.
How do you take Ipamorelin?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Lyophilized powder reconstituted with bacteriostatic water | No approved clinical dose (development discontinued) | 100 to 300 mcg per injection, 1 to 3 times daily |
Protocols
Conservative starter Anecdotal
- Dose
- 100 to 150 mcg
- Frequency
- Once daily
- Duration
- 8 to 12 weeks
Pre-sleep, to ride the natural growth-hormone pulse in deep sleep.
Standard Anecdotal
- Dose
- 200 to 300 mcg
- Frequency
- 1 to 2 times daily
- Duration
- 8 to 12 weeks, often 5 days on / 2 days off
200 mcg pre-sleep is the most-cited single dose in community reports.
Advanced Anecdotal
- Dose
- 300 mcg
- Frequency
- 2 to 3 times daily
- Duration
- 8 to 12 weeks
Spaced at least 6 hours apart; fasted morning, pre-workout, and pre-sleep.
CJC-1295 (no-DAC) stack Anecdotal
- Dose
- Ipamorelin 100 to 200 mcg plus CJC-1295 no-DAC 100 mcg
- Frequency
- 1 to 3 times daily
- Duration
- 8 to 12 weeks
The dominant community pairing. The no-DAC form has a short half-life that matches ipamorelin for synchronized pulses; the DAC form is avoided for this purpose.
Continuous low-dose (anti-aging clinics) Mixed
- Dose
- 100 to 200 mcg
- Frequency
- Once daily
- Duration
- Continuous, periodically reassessed
Favored by some longevity clinicians given the non-suppressive mechanism; considered fringe by the performance community.
How this score is calculated →
What are the benefits of Ipamorelin?
Upside contribution: 1.43
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.3 | 0.575 | |
| Breadth | 15% | 3.0 | 0.450 | |
| Evidence | 25% | 1.8 | 0.450 | |
| Speed | 10% | 3.0 | 0.300 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality | 15% | 3.0 | 0.450 | |
| Total | 2.425 |
Upside Rationale
The upside is concentrated in mechanism and tolerability, not in proven results. Ipamorelin's strongest asset is a clean, selective growth-hormone pulse; its weakest is that no human trial shows this translates into the body-composition, recovery, or sleep outcomes people want. Breadth and bioindividuality score moderately because growth hormone plausibly touches many systems and because response clearly varies by age and baseline. Speed scores well on the hormone pulse and early subjective sleep reports. Evidence is the dimension that drags the total down: the human file for marketed uses is effectively blank.
Efficacy (2.3/5.0): Efficacy is low because the growth-hormone pulse is real but its downstream payoff is undemonstrated in humans. Ipamorelin reliably releases growth hormone in animals and via its oral analogue, with strong receptor selectivity, per Raun 1998. What is missing is any human trial showing fat loss, muscle gain, or faster recovery. The one human efficacy test, for postoperative ileus in 114 patients, failed, per Beck 2014. Animal work shows anti-catabolic effects and bone growth, per Johansen 1999, but a confirmed hormone pulse without a confirmed human outcome cannot score as effective for the uses people care about.
Breadth of Benefits (3.0/5.0): Breadth is moderate because growth hormone plausibly influences many systems even though few are proven for ipamorelin. The animal and class data span bone (increased mineral content in rats, per Svensson 2000), nitrogen balance and muscle preservation under steroids, per Aagaard 2009, gut motility in a rodent model, per Venkova 2009, and a mechanistic case for sleep. That is genuinely broad reach in theory. The boundary is that breadth of mechanism is not breadth of proof; in humans, none of these systems has a controlled ipamorelin endpoint.
Evidence Quality (1.8/5.0): Evidence quality is the weakest dimension and the reason the overall score sits at neutral. There are no meta-analyses, no human efficacy RCTs for the marketed uses, and the single completed human efficacy trial failed, per Beck 2014. The supporting literature is animal studies plus class reviews that themselves call for the long-term human and cancer data that does not exist, per Sigalos and Pastuszak 2018. One widely-repeated figure, a roughly 95 percent subcutaneous bioavailability, has no published human source and should not be trusted. On the evidence hierarchy this lands at the mechanistic-and-anecdotal tier.
Speed of Onset (3.0/5.0): Speed is a relative bright spot. The growth-hormone pulse peaks around 40 minutes after a subcutaneous dose and clears within a few hours, so the acute pharmacology is fast. Subjectively, the most consistent community report is improved sleep within the first 1 to 2 weeks, consistent with the slow-wave-sleep effect seen with ghrelin-receptor activation, per Weikel 2003, while body-composition changes, if they appear, take months. The fast hormonal action is well-supported; the fast subjective effect is anecdotal but unusually consistent across user reports.
Durability (2.0/5.0): Durability is low because benefits depend on continued dosing. The growth-hormone pulse is transient and the axis returns to baseline between doses, so any effect fades when you stop. There is no evidence of lasting change after a cycle ends, and chronic rat dosing shows the pituitary adapts its secretory behavior over weeks, per Jimenez-Reina 2002. This is a maintain-to-keep-it tool, not a reset.
Bioindividuality Upside (3.0/5.0): Response varies enough that some users will notice clearly more than others. Older adults and those with a lower baseline growth-hormone output tend to show larger relative responses, while high visceral fat, elevated somatostatin tone from stress or recent carbohydrate intake, and an already-high IGF-1 ceiling all blunt the pulse. That spread means a motivated responder who times doses well around sleep and food may see the reported sleep benefit, while others feel little. Predictable modifiers exist, which is what lifts this above average.
What are the risks & downsides of Ipamorelin?
Downside contribution: 1.69 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 2.5 | 0.750 | |
| Side effects | 15% | 2.0 | 0.300 | |
| Cost | 5% | 2.5 | 0.125 | |
| Effort | 5% | 3.0 | 0.150 | |
| Opportunity | 5% | 2.5 | 0.125 | |
| Dependency | 15% | 2.5 | 0.375 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 2.275 | |||
| Harm subtotal × 1.4 | 2.625 | |||
| Opportunity subtotal × 1.0 | 0.400 | |||
| Combined downside | 3.025 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.685 |
Downside Rationale
The downside is dominated by uncertainty rather than acute danger. At standard subcutaneous doses ipamorelin has no documented intrinsic catastrophic effect, and its side effects are mild and reversible. The heavier weights come from open long-term safety questions tied to growth-hormone and IGF-1 biology, the daily-injection burden, and the opportunity cost of spending money and effort on an unproven peptide instead of better-evidenced basics. Dependency and reversibility are reassuring: the compound is non-suppressive and clears quickly. The most underappreciated risk is extrinsic: research-chemical sourcing.
Safety Risk (2.5/5.0): Safety risk is moderate, driven by unknowns rather than a confirmed catastrophic signal. Ipamorelin alone has no established intrinsic life-threatening effect at standard subcutaneous doses, so the catastrophic floor does not apply. A death cited in an intravenous gastric-motility study is not documented in the published literature and should be treated as unverified. The real concerns are theoretical and long-term: growth hormone raises IGF-1, which feeds proliferation pathways, so active cancer is an absolute contraindication and screening matters, per Sigalos and Pastuszak 2018. Fluid retention and glucose effects round out the watch list.
Side Effect Profile (2.0/5.0): Side effects are mild and dose-dependent. The common ones are water retention, injection-site reactions, transient headache, and occasional tingling or numbness on waking from fluid shifts. The notable positive is what is absent: ipamorelin does not meaningfully raise cortisol or prolactin and does not cause the strong hunger of GHRP-6, per Raun 1998. Most effects resolve within the first few weeks or with a dose reduction.
Financial Cost (2.5/5.0): Cost is moderate and ongoing. Compounded or research-grade ipamorelin commonly runs roughly 40 to 90 dollars per vial, and a daily-dosing cycle consumes vials steadily, with the popular CJC-1295 stack adding more. It is not expensive per dose, but the recurring spend on an unproven peptide is the relevant framing.
Time/Effort Burden (3.0/5.0): Effort is meaningful. Ipamorelin requires reconstitution with bacteriostatic water, subcutaneous injection one to three times daily, careful timing around food and sleep, and cycling. That is a real daily logistics load compared with an oral supplement or a lifestyle change, and the timing rules (no carbohydrates for about 2 hours pre-dose) add friction.
Opportunity Cost (2.5/5.0): Opportunity cost is moderate. The money, needles, and attention ipamorelin demands could go to interventions with stronger evidence for the same goals: resistance training and protein for body composition, sleep hygiene and light timing for sleep, and proven recovery basics. Ipamorelin stacks cleanly and does not obviously interfere with training, but for someone who has not nailed the fundamentals it can crowd out higher-yield work.
Dependency/Withdrawal (2.5/5.0): Dependency risk is low. Ipamorelin is non-suppressive: it does not shut down the reproductive axis, so no post-cycle therapy is needed, and there is no addictive craving. Benefits simply fade when dosing stops, which is functional reliance rather than withdrawal. Tolerance appears lower than with older secretagogues.
Reversibility (1.8/5.0): Reversibility is excellent, which is one of ipamorelin's genuine strengths. The short half-life and non-suppressive mechanism mean stopping returns the growth-hormone axis to baseline without a taper or lasting change. There is no documented permanent effect at standard doses, so a clean stop is straightforward.
Is Ipamorelin worth it?
Ipamorelin sits at neutral because it pairs a clean, well-understood mechanism with an almost empty human outcomes file. If you want a selective growth-hormone secretagogue, accept that the popular benefits are unproven in people, and can monitor IGF-1 and glucose with quality material, it is a reasonable, low-drama tool. If you expect evidence-backed fat loss or recovery, the data is not there, and the one human efficacy trial failed, per Beck 2014. The biggest real-world risk is not the molecule; it is sourcing unregulated peptides.
✅ Best for: Researchers and clinicians who value receptor selectivity and a mild side-effect profile over proven outcomes. Older adults with low baseline growth-hormone output, who tend to respond more. People chasing the most consistently reported effect, better sleep, who will judge it on their own response over a few weeks. Users who already have training, protein, and sleep dialed in and want a low-suppression add-on. Anyone who can obtain pharmaceutical-grade material with a third-party certificate of analysis and will track IGF-1 and fasting glucose.
❌ Avoid if: You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding, with no safety data. You have uncontrolled diabetes or insulin resistance, because growth hormone opposes insulin. You have congestive heart failure or fluid-overload risk. You compete in tested sport, since secretagogues are banned at all times under WADA S2. You cannot verify source quality, because contamination and immunogenicity from aggregated research-chemical peptides may exceed the intrinsic pharmacological risk.
Frequently Asked Questions
What does ipamorelin actually do?
Ipamorelin tells your pituitary to release a pulse of growth hormone by activating the ghrelin receptor (GHS-R1a), per Raun 1998. Its defining trait is selectivity: at growth-hormone-releasing doses it does not meaningfully raise cortisol or prolactin, unlike older peptides GHRP-6 and GHRP-2. The growth-hormone surge peaks around 40 minutes and clears within a few hours.
How much ipamorelin do people take, and when?
Community protocols commonly run 100 to 300 mcg subcutaneously, 1 to 3 times daily, with 200 mcg pre-sleep the single most-cited dose. These are not approved doses; ipamorelin has no FDA-approved indication. Most users cycle 8 to 12 weeks and avoid carbohydrates for about 2 hours before injecting, since insulin blunts the pulse. The dominant pairing adds CJC-1295 (no-DAC) at roughly 100 mcg.
What does the human evidence on ipamorelin actually show?
Human efficacy evidence for the marketed uses is essentially absent. The single completed human efficacy trial tested ipamorelin for postoperative ileus in 114 patients and failed its primary endpoint (p=0.15), after which development stopped, per Beck 2014. Everything claimed for body composition, recovery, anti-aging, and sleep extrapolates from animal studies, related secretagogues, and user reports.
Is ipamorelin safe long-term?
Short-term tolerability looks favorable, but long-term human safety data does not exist. The known side effects are mild and dose-dependent: water retention, injection-site reactions, headache, and occasional tingling. The real open questions are theoretical: growth hormone raises IGF-1, which feeds proliferation pathways, so cancer screening and glucose monitoring matter, per Sigalos and Pastuszak 2018.
Who should avoid ipamorelin?
Anyone with active or hormone-sensitive cancer, pregnancy, uncontrolled diabetes, congestive heart failure, or critical illness should avoid ipamorelin, because growth-hormone-axis stimulation can worsen those conditions. Competitive athletes must also avoid it: the World Anti-Doping Agency prohibits growth-hormone secretagogues at all times under category S2.
How fast should I expect effects from ipamorelin?
The growth-hormone pulse itself is fast, peaking near 40 minutes, but downstream effects are slow and unproven. User reports describe better sleep within 1 to 2 weeks, with body-composition changes, if any, taking 3 to 6 months. None of these timelines come from controlled trials, so treat them as community expectations rather than established results.
Ipamorelin vs CJC-1295: what is the difference, and why are they stacked?
Ipamorelin and CJC-1295 hit two different receptors that both raise growth hormone, which is why they are commonly stacked. Ipamorelin works through the ghrelin receptor; CJC-1295 works through the growth-hormone-releasing-hormone receptor. The community uses the no-DAC form of CJC-1295 because its short half-life matches ipamorelin for synchronized pulses, whereas the DAC form produces steady elevation. There is no human trial proving the stack outperforms either alone; the synergy claim is mechanistic and anecdotal.
Is ipamorelin legal, and how do you get quality material?
Ipamorelin is not FDA-approved and sits in a regulatory gray zone: it was recently removed from the Category 2 Do-Not-Compound list by procedure, but an advisory committee voted against compounding eligibility and a formal review is still pending. In practice it comes from compounding pharmacies or research-chemical vendors, where independent testing has repeatedly found underdosed or misidentified product. Quality material means a third-party certificate of analysis with HPLC purity and mass-spec identity, never a price-too-good-to-be-true vial.
What could change Ipamorelin's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The fastest path up is human outcome data, and the fastest path down is a documented safety signal. A single positive human RCT in body composition or sleep would lift Efficacy and Evidence together and move ipamorelin into worth-trying territory. A credible long-term harm signal, or confirmation of the disputed safety events, would push it toward caution. Because the current score rests on an empty human file, even modest real evidence in either direction would move it more than usual.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A well-run human RCT shows real body-composition or sleep benefit | Efficacy 2.3 to 3.5, Evidence 1.8 to 3.0 | 5.4 / 10 ⚖️ Neutral |
| Long-term human safety data confirms a clean profile | Evidence 1.8 to 2.6, Safety 2.5 to 2.0 | 5.2 / 10 ⚖️ Neutral |
| A credible cancer or cardiovascular harm signal emerges | Safety 2.5 to 4.0, Evidence 1.8 to 1.5 | 4.1 / 10 ⚠️ Caution |
| Pharmacy-grade access and clear legal status arrive | Cost 2.5 to 2.0, Effort 3.0 to 2.5 | 4.8 / 10 ⚖️ Neutral |
| Independent testing keeps finding underdosed or contaminated product | Safety 2.5 to 3.2 | 4.5 / 10 ⚖️ Neutral |
| A human trial fails to beat placebo for a marketed use | Efficacy 2.3 to 1.8, Evidence 1.8 to 1.5 | 4.6 / 10 ⚖️ Neutral |
Key Evidence Sources
- Raun 1998, Eur J Endocrinol: ipamorelin is the first selective growth-hormone secretagogue, with no significant ACTH or cortisol rise.. Defining selectivity characterization
- Beck 2014, Int J Colorectal Dis: phase 2 RCT (n=114) for postoperative ileus failed its primary endpoint (p=0.15); development discontinued.. Only completed human efficacy trial; negative
- Johansen 1999, Growth Horm IGF Res: ipamorelin induced longitudinal bone growth in rats.. Animal bone growth
- Svensson 2000, J Endocrinol: ipamorelin and GHRP-6 increased bone mineral content in adult female rats, via bone size not density.. Animal bone mineral content
- Andersen 2001, Growth Horm IGF Res: ipamorelin counteracted glucocorticoid-induced decrease in bone formation in adult rats.. Animal anti-catabolic bone
- Aagaard 2009, Growth Horm IGF Res: ipamorelin reduced glucocorticoid-induced hepatic nitrogen wasting by about 20 percent in rats.. Animal nitrogen balance
- Malmlof 1999, Growth Horm IGF Res: methylprednisolone did not block ipamorelin's growth-hormone release in rats.. Animal mechanism under steroid
- Venkova 2009, J Pharmacol Exp Ther: ipamorelin improved gastric dysmotility in a rodent postoperative-ileus model.. Animal motility (target that failed in humans)
- Sigalos and Pastuszak 2018, Sex Med Rev: review of growth-hormone-secretagogue safety and efficacy; calls for long-term safety data including cancer endpoints.. Growth-hormone-secretagogue class safety review; ipamorelin is in this parent class
- Sinha 2020, Transl Androl Urol: growth-hormone secretagogues and body composition in hypogonadal males; best data from other secretagogues.. Body-composition context for ipamorelin's parent secretagogue class
- Weikel 2003, Am J Physiol Endocrinol Metab: ghrelin infusion increased slow-wave sleep in 7 men (ghrelin receptor proxy).. Ghrelin-receptor sleep proxy related to ipamorelin (same GHS-R1a receptor)
- Ankersen 1998, J Med Chem: medicinal-chemistry series derived from ipamorelin.. Chemistry / structure
- Jimenez-Reina 2002, Histol Histopathol: chronic ipamorelin altered somatotroph response in young female rats.. Chronic pituitary adaptation (animal)
- WADA 2026 Prohibited List: growth-hormone secretagogues prohibited at all times under S2.. Anti-doping status for ipamorelin's parent secretagogue class
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- IGF 1 Pre | Expected Watch During | Expected Up
- Fasting Glucose During | Expected Watch
- HbA1c During | Expected Watch
Pulse Dimensions to Watch
- Sleep During | Expected Up | Primary
- Body During | Expected Watch | Secondary
- Energy During | Expected Up | Tertiary
Subjective Signals (Daily Voice Card)
- Sleep depth and morning grogginess Scale 1-5 | During | Expected Up
- Wrist or hand tingling on waking Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- New or worsening numbness or tingling (possible fluid-related nerve compression): reduce dose or stop.
- Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes.
- Any active or suspected cancer: do not use; growth-hormone-axis stimulation is contraindicated.
Other interventions for Sleep Quality
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.425 − 1.685 = -0.260
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.260 / 7) × 5 = 4.8 / 10
